Alkermes (NASDAQ:ALKS) Releases FY 2020 Pre-Market Earnings Guidance
Alkermes (NASDAQ:ALKS) issued an update on its FY 2020
Pre-Market earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.25-0.43 for the period, compared to the Thomson Reuters consensus estimate of $0.44. The company issued revenue guidance of $1.03-1.08 billion, compared to the consensus revenue estimate of $1.06 billion.Alkermes also updated its FY20 guidance to $0.25 to $0.43 EPS.
Alkermes stock traded up $0.12 during mid-day trading on Friday, reaching $17.77. 3,334,635 shares of the company were exchanged, compared to its average volume of 1,555,217. The business has a fifty day moving average of $18.89 and a 200 day moving average of $20.09. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.42 and a current ratio of 2.69. The firm has a market cap of $3.01 billion, a P/E ratio of -13.78 and a beta of 1.97. Alkermes has a 12-month low of $16.65 and a 12-month high of $37.75.
Alkermes (NASDAQ:ALKS) last posted its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.18. Alkermes had a negative return on equity of 6.08% and a negative net margin of 18.71%. The company had revenue of $412.70 million during the quarter, compared to analyst estimates of $404.45 million. During the same quarter in the prior year, the business earned $0.34 earnings per share. Alkermes’s revenue was up 30.7% on a year-over-year basis. Sell-side analysts predict that Alkermes will post -0.16 EPS for the current year.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
Featured Article: Depreciation
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.